Browse
Submit Data
Databases
API
Help

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Redetermination of ?-Ba(PO3)2.

ABSTRACT: In comparison with the previous structure determination of the ?-modification of barium catena-polyphosphate that was based on Weissenberg film data [Grenier et al. (1967 ?). Bull. Soc. Fr. Minéral. Cristallogr. 90, 24-31], the current CCD-data-based redetermination reveals all atoms with anisotropic displacement parameters, standard uncertainties for the atomic coordinates, and the determination of the absolute structure. Moreover, a much higher accuracy in terms of the bond-length distribution for the polyphosphate chain, with two shorter and two longer P-O distances, was achieved. The structure consists of polyphosphate chains extending parallel to [100] with a periodicity of two PO4 tetra-hedra. The Ba(2+) cations are located between the chains and are surrounded by ten O atoms in the form of a distorted coordination polyhedron, with Ba-O distances ranging from 2.765?(3) to 3.143?(3)?Å, also reflecting the higher precision of the current redetermination.

SUBMITTER: Weil M

PROVIDER: S-EPMC3998241 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Redetermination of β-Ba(PO3)2.

Weil Matthias M

Acta crystallographica. Section E, Structure reports online 20140111 Pt 2

In comparison with the previous structure determination of the β-modification of barium catena-polyphosphate that was based on Weissenberg film data [Grenier et al. (1967 ▶). Bull. Soc. Fr. Minéral. Cristallogr. 90, 24-31], the current CCD-data-based redetermination reveals all atoms with anisotropic displacement parameters, standard uncertainties for the atomic coordinates, and the determination of the absolute structure. Moreover, a much higher accuracy in terms of the bond-length distribution ...[more]

PMID: 24764803

Similar Datasets

Redetermination of Ba(2)CdTe(3) from single-crystal X-ray data.

Project description:The previous structure determination of the title compound, dibarium tritelluridocadmate, was based on powder X-ray diffraction data [Wang & DiSalvo (1999 ?). J. Solid State Chem.148, 464-467]. In the current redetermination from single-crystal X-ray data, all atoms were refined with anisotropic displacement parameters. The previous structure report is generally confirmed, but with some differences in bond lengths. Ba(2)CdTe(3) is isotypic with Ba(2)MX(3) (M = Mn, Cd; X = S, Se) and features (1) (?)[CdTe(2/2)Te(2/1)](4-) chains of corner-sharing CdTe(4) tetra-hedra running parallel [010]. The two Ba(2+) cations are located between the chains, both within distorted monocapped trigonal-prismatic coordination polyhedra. All atoms in the structure are located on a mirror plane.

| S-EPMC3470123 | biostudies-literature

Crystal structures of the triple perovskites Ba2K2Te2O9 and Ba2KNaTe2O9, and redetermination of the double perovskite Ba2CaTeO6.

Project description:Single crystals of Ba2K2Te2O9 (dibarium dipotassium nona-oxidoditellurate), (I), Ba2KNaTe2O9 (dibarium potassium sodium nona-oxidoditellurate), (II), and Ba2CaTeO6 (dibarium calcium hexa-oxidotellurate), (III), were obtained from KNO3/KI or KNO3/NaNO3 flux syntheses in platinum crucibles for (I) and (II), or porcelain crucibles for (III). (I) and (II) are isotypic and are members of triple perovskites with general formula A2[12co]A'[12co]B2[6o]B'[6o]O9. They crystallize in the 6H-BaTiO3 structure family in space-group type P63/mmc, with the A, A', B and B' sites being occupied by K, Ba, Te and a second Ba in (I), and in (II) by mixed-occupied (Ba/K), Ba, Te and Na sites, respectively. (III) adopts the A2[12co]B'[6o]B''[6o]O6 double perovskite structure in space-group type Fmm, with Ba, Ca and Te located on the A, B' and B'' sites, respectively. The current refinement of (III) is based on single-crystal X-ray data. It confirms the previous refinement from X-ray powder diffraction data [Fu et al. (2008). J. Solid State Chem.181, 2523-2529], but with higher precision.

| S-EPMC6038633 | biostudies-literature

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5.

Project description: Not available

| S-EPMC9239574 | biostudies-literature

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.

Project description: Not available

| S-EPMC9258748 | biostudies-literature

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.

Project description:SARS-CoV-2 Omicron variant has presented significant challenges to current antibodies and vaccines. Herein, we systematically compared the efficacy of 50 human monoclonal antibodies (mAbs), covering the seven identified epitope classes of the SARS-CoV-2 RBD, against Omicron sub-variants BA.1, BA.1.1, BA.2, and BA.3. Binding and pseudovirus-based neutralizing assays revealed that 37 of the 50 mAbs lost neutralizing activities, whereas the others displayed variably decreased activities against the four Omicron sub-variants. BA.2 was found to be more sensitive to RBD-5 antibodies than the other sub-variants. Furthermore, a quaternary complex structure of BA.1 RBD with three mAbs showing different neutralizing potencies against Omicron provided a basis for understanding the immune evasion of Omicron sub-variants and revealed the lack of G446S mutation accounting for the sensitivity of BA.2 to RBD-5 mAbs. Our results may guide the application of the available mAbs and facilitate the development of universal therapeutic antibodies and vaccines against COVID-19.

| S-EPMC9197780 | biostudies-literature

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Project description:The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa's Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the receptor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.

| S-EPMC9181312 | biostudies-literature

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5.

Project description:The replacement of the Omicron BA.1 variant of SARS-CoV-2 by the BA.2 and the rapid growth of the BA.5 sub lineage, which have both different sets of mutations in the spike glycoprotein, alters the spectrum of activity of therapeutic antibodies currently licensed in the European Union. Using clinical strains of the Omicron BA.2 and BA.5 variants, we compared the neutralising power of monoclonal antibodies against the Omicron BA.1, BA.2 and BA.5 variants, using an ancestral strain (lineage B.1, D614G) and a Delta variant strain as reference. Sotrovimab/Vir-7831 is less active against BA.2 than against BA.1 (fold change reduction ~ 1,4) and even less active against BA.5 (fold change reduction ~ 2.7). Within the Evusheld /AZD7442 cocktail, Cilgavimab/AZD1061 is more active against BA.2 and BA.5 than against BA.1 (fold change increase ~ 32), whilst the very low activity of Tixagevimab/AZD8895 against BA.1 is not enhanced against BA.2 nor BA.5. In total, compared to BA.1, the activity of the Evusheld/AZD7442 is significantly improved against BA.2 while BA.5 is intermediate but closer to BA.2.

| S-EPMC9308029 | biostudies-literature

Classification of Omicron BA.1, BA.1.1 and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data.

Project description:ObjectiveRecently, the Omicron strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread and replaced the previously dominant Delta strain. Several Omicron sublineages (BA.1, BA.1.1 and BA.2) have been identified, with in vitro and preclinical reports showing that the pathogenicity and therapeutic efficacy differs between BA.1 and BA.2. We sought to develop a TaqMan assay to identify these subvariants.MethodsA TaqMan assay was constructed for rapid identification and genotyping of Omicron sublineages with 171 samples. We analyzed three characteristic mutations of the spike gene, Δ69-70, G339D and Q493R, by TaqMan assay. The accuracy of the TaqMan assay was examined by comparing its results with the results of whole genome sequencing (WGS) analysis.ResultsA total of 171 SARS-CoV-2 positive samples were analyzed by WGS and TaqMan assay. The 127 samples determined as BA.1/BA.1.1 by WGS were all positive for Δ69-70, G339D and Q493R by TaqMan assay. Forty-two samples determined as BA.2 by WGS were negative for Δ69-70 but positive for G339D and Q493R by TaqMan. Two samples with G339N were determined to be inconclusive by the TaqMan method. Except for these two samples, the concordance rate between WGS and the TaqMan assay was 100% (169/169).ConclusionTaqMan assays targeting characteristic mutations are useful for identification and discrimination of Omicron sublineages.

| S-EPMC9233878 | biostudies-literature

Redetermination of AgPO(3).

Project description:Single crystals of silver(I) polyphosphate(V), AgPO(3), were prepared via a phospho-ric acid melt method using a solution of Ag(3)PO(4) in H(3)PO(4). In comparison with the previous study based on single-crystal Weissenberg photographs [Jost (1961 ?). Acta Cryst. 14, 779-784], the results were mainly confirmed, but with much higher precision and with all displacement parameters refined anisotropically. The structure is built up from two types of distorted edge- and corner-sharing [AgO(5)] polyhedra, giving rise to multidirectional ribbons, and from two types of PO(4) tetra-hedra linked into meandering chains (PO(3))(n) spreading parallel to the b axis with a repeat unit of four tetra-hedra. The calculated bond-valence sum value of one of the two Ag(I) ions indicates a significant strain of the structure.

| S-EPMC3052054 | biostudies-literature

Redetermination of MgCrO4·5H2O.

Project description:The CCD-data based redetermination of the crystal structure of the title compound, magnesium chromate(VI) penta-hydrate, confirms in principle the previous study based on precession film data [Bertrand et al. (1971 ?). C. R. Hebd. Seances Acad. Sci. Serie C, 272, 530-533.], but with all atoms refined with anisotropic displacement parameters and with all H atoms localized. This allowed an unambiguous assignment of the hydrogen-bonding pattern. MgCrO4·5H2O adopts the MgSO4·5H2O structure type. It contains two Mg(2+) sites on special positions with site symmetry -1, one tetra-hedral CrO4 group and five water mol-ecules. Four of them coordinate to the Mg(2+) cation, and one is an uncoordinating lattice water mol-ecule. The octa-hedral environment of the Mg(2+) cation is completed by two axial O atoms of CrO4 tetra-hedra. This arrangement leads to the formation of chains parallel to [011]. Adjacent chains are linked through O-H?O hydrogen bonds (one of them bifurcated), involving both the coordi-nating and lattice water mol-ecules, into a three-dimensional network.

| S-EPMC3793667 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data